Improving long-term survival in diffuse intrinsic pontine glioma

References

• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016 Jun;131(6):803–820..
   PubMed Web of Science ®Google Scholar
• Cooney T, Lane A, Bartels U, et al. Contemporary survival endpoints: an international diffuse intrinsic pontine glioma registry study. Neuro Oncol. 2017 Sep 1;19(9):1279–1280.
   PubMed Web of Science ®Google Scholar
• Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N, et al. Clinical, radiologic, pathologic, and molecular characteristics of long-term survivors of diffuse intrinsic pontine glioma (DIPG): A Collaborative report from the international and European Society for Pediatric Oncology DIPG registries. J Clin Oncol. 2018 Jul 1;36(19):1963–1972.
   PubMed Web of Science ®Google Scholar
• Veldhuijzen van Zanten SE, Jansen MH, Sanchez Aliaga E, et al. A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands. Expert Rev Anticancer Ther. 2015 Feb;15(2):157–164..
   PubMed Web of Science ®Google Scholar
• Hankinson TC, Campagna EJ, Foreman NK, et al. Interpretation of magnetic resonance images in diffuse intrinsic pontine glioma: a survey of pediatric neurosurgeons. J Neurosurg Pediatr. 2011 Jul;8(1):97–102..
   PubMed Web of Science ®Google Scholar
• Albright AL, Packer RJ, Zimmerman R, et al. Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children’s Cancer Group. Neurosurgery. 1993 Dec;33(6):1026–1029. discussion 1029-30.
   PubMed Web of Science ®Google Scholar
• Poussaint TY, Kocak M, Vajapeyam S, et al. MRI as a central component of clinical trials analysis in brainstem glioma: a report from the pediatric brain tumor consortium (PBTC). Neuro Oncol. 2011 Apr;13(4):417–427.
   PubMed Web of Science ®Google Scholar
• Veldhuijzen van Zanten SEM, Lane A, Heymans MW, et al. External validation of the diffuse intrinsic pontine glioma survival prediction model: a collaborative report from the International DIPG registry and the SIOPE DIPG registry. J Neurooncol. 2017 Aug;134(1):231–240.
   PubMed Web of Science ®Google Scholar
• Yamasaki F, Kurisu K, Kajiwara Y, et al. Magnetic resonance spectroscopic detection of lactate is predictive of a poor prognosis in patients with diffuse intrinsic pontine glioma. Neuro Oncol. 2011 Jul;13(7):791–801.
   PubMed Web of Science ®Google Scholar
• Poussaint TY, Vajapeyam S, Ricci KI, et al. Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the pediatric brain tumor consortium. Neuro Oncol. 2016 May;18(5):725–734.
   PubMed Web of Science ®Google Scholar
• Sedlacik J, Winchell A, Kocak M, et al. MR imaging assessment of tumor perfusion and 3D segmented volume at baseline, during treatment, and at tumor progression in children with newly diagnosed diffuse intrinsic pontine glioma. AJNR Am J Neuroradiol. 2013 Jul;34(7):1450–1455.
   PubMed Web of Science ®Google Scholar
• Verma N, Cowperthwaite MC, Burnett MG, et al. Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies. Neuro Oncol. 2013 May;15(5):515–534..
   PubMed Web of Science ®Google Scholar
• Carceller F, Jerome NP, Fowkes LA, et al. Post-radiotherapy apparent diffusion coefficient (ADC) in children and young adults with high-grade gliomas and diffuse intrinsic pontine gliomas. Pediatr Hematol Oncol. 2019 Mar;36(2):103–112..
   PubMed Web of Science ®Google Scholar
• Calmon R, Puget S, Varlet P, et al. Cerebral blood flow changes after radiation therapy identifies pseudoprogression in diffuse intrinsic pontine gliomas. Neuro Oncol. 2018 Jun 18;20(7):994–1002.
   PubMed Web of Science ®Google Scholar
• Carceller F, Fowkes LA, Khabra K, et al. Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma. J Neurooncol. 2016 Aug;129(1):109–121.
   PubMed Web of Science ®Google Scholar
• Zukotynski KA, Fahey FH, Kocak M, et al. Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium. J Nucl Med. 2011 Feb;52(2):188–195.
   PubMed Web of Science ®Google Scholar
• Zukotynski KA, Vajapeyam S, Fahey FH, et al. Correlation of (18)F-FDG PET and MRI apparent diffusion coefficient histogram metrics with survival in diffuse intrinsic pontine glioma: a report from the pediatric brain tumor consortium. J Nucl Med. 2017 Aug;58(8):1264–1269.
   PubMed Web of Science ®Google Scholar
• Goldman S, Pirotte BJ. Brain tumors. Methods Mol Biol. 2011;727:291–315.
   PubMedGoogle Scholar
• Tinkle CL, Duncan EC, Doubrovin M, et al. Evaluation of (11)C-methionine PET and anatomic MRI associations in diffuse intrinsic pontine glioma. J Nucl Med. 2019 Mar;60(3):312–319.
   PubMed Web of Science ®Google Scholar
• Becher OJ, Hambardzumyan D, Walker TR, et al. Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res. 2010 Mar 15;70(6):2548–2557.
   PubMed Web of Science ®Google Scholar
• Grasso CS, Tang Y, Truffaux N, et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med. 2015 Jun;21(6):555–559.
   PubMed Web of Science ®Google Scholar
• Buczkowicz P, Hoeman C, Rakopoulos P, et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet. 2014 May;46(5):451–456.
   PubMed Web of Science ®Google Scholar
• Welby JP, Kaptzan T, Wohl A, et al. Current murine models and new developments in H3K27M diffuse midline gliomas. Front Oncol. 2019;9:92.
   PubMed Web of Science ®Google Scholar
• Plessier A, Le Dret L, Varlet P, et al. New in vivo avatars of diffuse intrinsic pontine gliomas (DIPG) from stereotactic biopsies performed at diagnosis. Oncotarget. 2017 Aug 8; 8(32): 52543–52559.
   PubMedGoogle Scholar
• Hamisch C, Kickingereder P, Fischer M, et al. Update on the diagnostic value and safety of stereotactic biopsy for pediatric brainstem tumors: a systematic review and meta-analysis of 735 cases. J Neurosurg Pediatr. 2017 Sep;20(3):261–268..
   PubMed Web of Science ®Google Scholar
• Pfaff E, El Damaty A, Balasubramanian GP, et al. Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. Eur J Cancer. 2019 Jun;114:27–35.
   PubMed Web of Science ®Google Scholar
• Mueller S, Jain P, Liang WS, et al. A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric neuro-oncology consortium. Int J Cancer. 2019 Oct 1;145(7):1889–1901.
   PubMed Web of Science ®Google Scholar
• Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017 Aug 16;9(403):403.
   Web of Science ®Google Scholar
• Huang TY, Piunti A, Lulla RR, et al. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma. Acta Neuropathol Commun. 2017 Apr 17;5(1):28.
   PubMed Web of Science ®Google Scholar
• Panditharatna E, Kilburn LB, Aboian MS, et al. Clinically relevant and minimally invasive tumor surveillance of pediatric diffuse midline gliomas using patient-derived liquid biopsy. Clin Cancer Res. 2018 Dec 1;24(23):5850–5859.
   PubMed Web of Science ®Google Scholar
• Lu VM, Power EA, Zhang L, et al. Liquid biopsy for diffuse intrinsic pontine glioma: an update. J Neurosurg Pediatr. 2019;6:1–8.
   Google Scholar
• Wu G, Broniscer A, McEachron TA, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet. 2012 Jan 29;44(3):251–253.
   PubMed Web of Science ®Google Scholar
• Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012 Jan 29;482(7384):226–231.
   PubMed Web of Science ®Google Scholar
• Khuong-Quang DA, Buczkowicz P, Rakopoulos P, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 2012 Sep;124(3):439–447.
   PubMed Web of Science ®Google Scholar
• Castel D, Philippe C, Calmon R, et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol. 2015 Dec;130(6):815–827..
   PubMed Web of Science ®Google Scholar
• Bender S, Tang Y, Lindroth AM, et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell. 2013 Nov 11;24(5):660–672.
   PubMed Web of Science ®Google Scholar
• Nagaraja S, Quezada MA, Gillespie SM, et al. Histone variant and cell context determine H3K27M reprogramming of the enhancer landscape and oncogenic state. Mol Cell. 2019 Dec 19;76(6):965–980 e12.
   PubMed Web of Science ®Google Scholar
• Marques S, van Bruggen D, Vanichkina DP, et al. Transcriptional convergence of oligodendrocyte lineage progenitors during development. Dev Cell. 2018 Aug 20;46(4):504–517 e7.
   PubMed Web of Science ®Google Scholar
• Gillespie S, Monje M. An active role for neurons in glioma progression: making sense of Scherer’s structures. Neuro Oncol. 2018 Sep 3;20(10):1292–1299.
   PubMed Web of Science ®Google Scholar
• Anderson JL, Muraleedharan R, Oatman N, et al. The transcription factor Olig2 is important for the biology of diffuse intrinsic pontine gliomas. Neuro Oncol. 2017 Aug 1;19(8):1068–1078.
   PubMed Web of Science ®Google Scholar
• Lindquist RA, Guinto CD, Rodas-Rodriguez JL, et al. Identification of proliferative progenitors associated with prominent postnatal growth of the pons. Nat Commun. 2016 May;18(7):11628..
   Google Scholar
• Loveson KF, Fillmore HL. Intersection of brain development and paediatric diffuse midline gliomas: potential role of microenvironment in tumour growth. Brain Sci. 2018 Nov 16;8(11):200.
   PubMed Web of Science ®Google Scholar
• Buczkowicz P, Hawkins C. Pathology, molecular genetics, and epigenetics of diffuse intrinsic pontine glioma. Front Oncol. 2015;5:147.
   PubMed Web of Science ®Google Scholar
• Hoeman C, Shen C, Becher OJ. CDK4/6 and PDGFRA signaling as therapeutic targets in diffuse intrinsic pontine glioma. Front Oncol. 2018;8:191.
   PubMed Web of Science ®Google Scholar
• Silveira AB, Kasper LH, Fan Y, et al. H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo. Acta Neuropathol. 2019 Apr;137(4):637–655..
   PubMed Web of Science ®Google Scholar
• Mackay A, Burford A, Carvalho D, et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell. 2017 Oct 9;32(4):520–537 e5.
   PubMed Web of Science ®Google Scholar
• Vinci M, Burford A, Molinari V, et al. Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells. Nat Med. 2018 Aug;24(8):1204–1215.
   PubMed Web of Science ®Google Scholar
• Bradley KA, Zhou T, McNall-Knapp RY, et al. Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children’s oncology group phase 2 study. Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):e55–60.
   PubMed Web of Science ®Google Scholar
• Gallitto M, Lazarev S, Wasserman I, et al. Role of radiation therapy in the management of diffuse intrinsic pontine glioma: a systematic review. Adv Radiat Oncol. 2019 Jul-Sep;4(3):520–531.
   PubMedGoogle Scholar
• Packer RJ, Boyett JM, Zimmerman RA, et al. Hyperfractionated radiation therapy (72 Gy) for children with brain stem gliomas. A childrens cancer group phase I/II trial. Cancer. 1993 Aug 15;72(4):1414–1421.
   PubMed Web of Science ®Google Scholar
• Packer RJ, Prados M, Phillips P, et al. Treatment of children with newly diagnosed brain stem gliomas with intravenous recombinant beta-interferon and hyperfractionated radiation therapy: a childrens cancer group phase I/II study. Cancer. 1996 May 15;77(10):2150–2156.
   PubMed Web of Science ®Google Scholar
• Mandell LR, Kadota R, Freeman C, et al. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):959–964.
   PubMed Web of Science ®Google Scholar
• Hankinson TC, Patibandla MR, Green A, et al. Hypofractionated radiotherapy for children with diffuse intrinsic pontine gliomas. Pediatr Blood Cancer. 2016 Apr;63(4):716–718.
   PubMed Web of Science ®Google Scholar
• Zaghloul MS, Eldebawy E, Ahmed S, et al. Hypofractionated conformal radiotherapy for pediatric diffuse intrinsic pontine glioma (DIPG): a randomized controlled trial. Radiother Oncol. 2014 Apr;111(1):35–40.
   PubMed Web of Science ®Google Scholar
• Freese C, Takiar V, Fouladi M, et al. Radiation and subsequent reirradiation outcomes in the treatment of diffuse intrinsic pontine glioma and a systematic review of the reirradiation literature. Pract Radiat Oncol. 2017 Mar - Apr;7(2):86–92.
   PubMed Web of Science ®Google Scholar
• Janssens GO, Gandola L, Bolle S, et al. Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. Eur J Cancer. 2017 Mar;73:38–47.
   PubMed Web of Science ®Google Scholar
• Lassaletta A, Strother D, Laperriere N, et al. Reirradiation in patients with diffuse intrinsic pontine gliomas: the Canadian experience. Pediatr Blood Cancer. 2018 Jun;65(6):e26988.
   PubMed Web of Science ®Google Scholar
• Osorio DS, Patel N, Ji L, et al. Pre-irradiation intensive induction and marrow-ablative consolidation chemotherapy in young children with newly diagnosed high-grade brainstem gliomas: report of the “head-start” I and II clinical trials. J Neurooncol. 2018 Dec;140(3):717–725.
   PubMed Web of Science ®Google Scholar
• Jansen MH, van Vuurden DG, Vandertop WP, et al. Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. Cancer Treat Rev. 2012 Feb;38(1):27–35.
   PubMed Web of Science ®Google Scholar
• Cohen KJ, Heideman RL, Zhou T, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children’s oncology group. Neuro Oncol. 2011 Apr;13(4):410–416.
   PubMed Web of Science ®Google Scholar
• Chassot A, Canale S, Varlet P, et al. Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol. 2012 Jan;106(2):399–407.
   PubMed Web of Science ®Google Scholar
• El-Khouly FE, Veldhuijzen van Zanten SEM, Santa-Maria Lopez V, et al. Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand? J Neurooncol. 2019 Oct;145(1):177–184.
   PubMed Web of Science ®Google Scholar
• Alli S, Figueiredo CA, Golbourn B, et al. Brainstem blood brain barrier disruption using focused ultrasound: A demonstration of feasibility and enhanced doxorubicin delivery. J Control Release. 2018 Jul;10(281):29–41.
   Google Scholar
• Bredlau AL, Dixit S, Chen C, et al. Nanotechnology applications for diffuse intrinsic pontine glioma. Curr Neuropharmacol. 2017;15(1):104–115.
   PubMed Web of Science ®Google Scholar
• Himes BT, Zhang L, Daniels DJ. Treatment strategies in diffuse midline gliomas with the H3K27M mutation: the role of convection-enhanced delivery in overcoming anatomic challenges. Front Oncol. 2019;9:31.
   PubMed Web of Science ®Google Scholar
• Souweidane MM, Kramer K, Pandit-Taskar N, et al. Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. Lancet Oncol. 2018 Aug;19(8):1040–1050.
   PubMed Web of Science ®Google Scholar
• Anderson RC, Kennedy B, Yanes CL, et al. Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children. J Neurosurg Pediatr. 2013 Mar;11(3):289–295.
   PubMed Web of Science ®Google Scholar
• Heiss JD, Jamshidi A, Shah S, et al. Phase I trial of convection-enhanced delivery of IL13-Pseudomonas toxin in children with diffuse intrinsic pontine glioma. J Neurosurg Pediatr. 2018 Dec 7;23(3):333–342.
   PubMed Web of Science ®Google Scholar
• Tosi U, Kommidi H, Bellat V, et al. Real-time, in vivo correlation of molecular structure with drug distribution in the brain striatum following convection enhanced delivery. ACS Chem Neurosci. 2019 May 15;10(5):2287–2298.
   PubMed Web of Science ®Google Scholar
• Huang T, Garcia R, Qi J, et al. Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes. Oncotarget. 2018 Dec 14;9(98):37112–37124.
   PubMedGoogle Scholar
• Piunti A, Hashizume R, Morgan MA, et al. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med. 2017 Apr;23(4):493–500.
   PubMed Web of Science ®Google Scholar
• Hennika T, Hu G, Olaciregui NG, et al. Pre-clinical study of panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models. PLoS One. 2017;12(1):e0169485.
   PubMed Web of Science ®Google Scholar
• Kommidi H, Tosi U, Maachani UB, et al. (18)F-radiolabeled panobinostat allows for positron emission tomography guided delivery of a histone deacetylase inhibitor. ACS Med Chem Lett. 2018 Feb 8;9(2):114–119.
   PubMed Web of Science ®Google Scholar
• Pal S, Kozono D, Yang X, et al. Dual HDAC and PI3K inhibition abrogates NFkappaB- and FOXM1-mediated DNA damage response to radiosensitize pediatric high-grade gliomas. Cancer Res. 2018 Jul 15;78(14):4007–4021.
   PubMed Web of Science ®Google Scholar
• Hashizume R, Andor N, Ihara Y, et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med. 2014 Dec;20(12):1394–1396.
   PubMed Web of Science ®Google Scholar
• Katagi H, Louis N, Unruh D, et al. Radiosensitization by histone H3 demethylase inhibition in diffuse intrinsic pontine glioma. Clin Cancer Res. 2019 Sep 15;25(18):5572–5583.
   PubMed Web of Science ®Google Scholar
• Anastas JN, Zee BM, Kalin JH, et al. Re-programing chromatin with a bifunctional LSD1/HDAC inhibitor induces therapeutic differentiation in DIPG. Cancer Cell. 2019 Nov 11;36(5):528–544 e10.
   PubMed Web of Science ®Google Scholar
• Mohammad F, Weissmann S, Leblanc B, et al. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat Med. 2017 Apr;23(4):483–492..
   PubMed Web of Science ®Google Scholar
• Stafford JM, Lee CH, Voigt P, et al. Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma. Sci Adv. 2018 Oct;4(10):eaau5935..
   PubMed Web of Science ®Google Scholar
• Kong Y, Ai C, Dong F, et al. Targeting of BMI-1 with PTC-209 inhibits glioblastoma development. Cell Cycle. 2018;17(10):1199–1211..
   PubMed Web of Science ®Google Scholar
• Filbin MG, Tirosh I, Hovestadt V, et al. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science. 2018 Apr 20;360(6386):331–335.
   PubMed Web of Science ®Google Scholar
• Kumar SS, Sengupta S, Lee K, et al. BMI-1 is a potential therapeutic target in diffuse intrinsic pontine glioma. Oncotarget. 2017 Sep 8;8(38):62962–62975.
   PubMedGoogle Scholar
• Zhang Y, Dong W, Zhu J, et al. Combination of EZH2 inhibitor and BET inhibitor for treatment of diffuse intrinsic pontine glioma. Cell Biosci. 2017;7(1):56..
   PubMedGoogle Scholar
• Nagaraja S, Vitanza NA, Woo PJ, et al. Transcriptional dependencies in diffuse intrinsic pontine glioma. Cancer Cell. 2017 May 8;31(5):635–652 e6.
   PubMed Web of Science ®Google Scholar
• Koncar RF, Dey BR, Stanton AJ, et al. Identification of novel RAS signaling therapeutic vulnerabilities in diffuse intrinsic pontine gliomas. Cancer Res. 2019 Aug 15;79(16):4026–4041.
   PubMed Web of Science ®Google Scholar
• Li X, Wu C, Chen N, et al. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget. 2016 May 31;7(22):33440–33450.
   PubMedGoogle Scholar
• YL W, UB M, Schweitzer M, et al. Dual inhibition of PI3K/AKT and MEK/ERK pathways induces synergistic antitumor effects in diffuse intrinsic pontine glioma cells. Transl Oncol. 2017 Apr;10(2):221–228.
   PubMed Web of Science ®Google Scholar
• Koschmann C, Farooqui Z, Kasaian K, et al. Multi-focal sequencing of a diffuse intrinsic pontine glioma establishes PTEN loss as an early event. NPJ Precis Oncol. 2017;1(1):32.
   PubMedGoogle Scholar
• Broniscer A, Baker SD, Wetmore C, et al. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clin Cancer Res. 2013 Jun 1;19(11):3050–3058.
   PubMed Web of Science ®Google Scholar
• Mittapalli RK, Chung AH, Parrish KE, et al. ABCG2 and ABCB1 limit the efficacy of dasatinib in a PDGF-B-driven brainstem glioma model. Mol Cancer Ther. 2016 May;15(5):819–829.
   PubMed Web of Science ®Google Scholar
• Miyahara H, Yadavilli S, Natsumeda M, et al. The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma. Cancer Lett. 2017 Aug 1;400:110–116.
   PubMed Web of Science ®Google Scholar
• Becher OJ, Gilheeney SW, Khakoo Y, et al. A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors. Pediatr Blood Cancer. 2017 Jul;64(7):e26409..
   PubMed Web of Science ®Google Scholar
• Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet. 2014 May;46(5):462–466..
   PubMed Web of Science ®Google Scholar
• Hoeman CM, Cordero FJ, Hu G, et al. ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis. Nat Commun. 2019 Mar 4;10(1):1023.
   PubMedGoogle Scholar
• Asby DJ, Killick-Cole CL, Boulter LJ, et al. Combined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity. Cancer Manag Res. 2018;10:3483–3500.
   PubMed Web of Science ®Google Scholar
• de Gooijer MC, Zhang P, Thota N, et al. P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib. Invest New Drugs. 2015 Oct;33(5):1012–1019..
   PubMed Web of Science ®Google Scholar
• Becher OJ. CDK4/6 and diffuse intrinsic pontine glioma - Evaluate at diagnosis? EBioMedicine. 2019 Jun;44:16–17.
   PubMed Web of Science ®Google Scholar
• Raub TJ, Wishart GN, Kulanthaivel P, et al. Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft. Drug Metab Dispos. 2015 Sep;43(9):1360–1371.
   PubMed Web of Science ®Google Scholar
• Caretti V, Hiddingh L, Lagerweij T, et al. WEE1 kinase inhibition enhances the radiation response of diffuse intrinsic pontine gliomas. Mol Cancer Ther. 2013 Feb;12(2):141–150.
   PubMed Web of Science ®Google Scholar
• Kline CLB, Ralff MD, Lulla AR, et al. Role of dopamine receptors in the anticancer activity of ONC201. Neoplasia. 2018 Jan;20(1):80–91.
   PubMed Web of Science ®Google Scholar
• Graves PR, Aponte-Collazo LJ, Fennell EMJ, et al. Mitochondrial protease ClpP is a target for the anticancer compounds ONC201 and related analogues. ACS Chem Biol. 2019 May 17;14(5):1020–1029.
   PubMed Web of Science ®Google Scholar
• Arrillaga-Romany I, Chi AS, Allen JE, et al. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget. 2017 Oct 3;8(45):79298–79304.
   PubMedGoogle Scholar
• Arrillaga-Romany I, Odia Y, Prabhu VV, et al. Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. Neuro Oncol. 2020 Jan 11;22(1):94–102.
   PubMed Web of Science ®Google Scholar
• Hall MD, Odia Y, Allen JE, et al. First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report. J Neurosurg Pediatr. 2019;5:1–7.
   Google Scholar
• Cohen JV, Buchbinder EI. The evolution of adjuvant therapy for melanoma. Curr Oncol Rep. 2019 Nov 25;21(12):106.
   PubMed Web of Science ®Google Scholar
• Lieberman NAP, DeGolier K, Kovar HM, et al. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy. Neuro Oncol. 2019 Jan 1;21(1):83–94.
   PubMed Web of Science ®Google Scholar
• Lin GL, Nagaraja S, Filbin MG, et al. Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma. Acta Neuropathol Commun. 2018 Jun 28;6(1):51.
   PubMedGoogle Scholar
• Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.
   PubMed Web of Science ®Google Scholar
• Hwang E, Onar A, Young-Poussaint T, et al. IMMU-09. Outcome of patients with recurrent diffuse intrinsic pontine glioma (DIPG) treated with pembrolizumab (ANTI-PD-1): a pediatric brain tumor consortium study (PBTC045). Neuro Oncol. 2018;20(suppl_2):i100–i100.
   Google Scholar
• Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017 Dec 21;377(25):2500–2501.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015 Jun 25;372(26):2509–2520.
   PubMed Web of Science ®Google Scholar
• Johnson A, Severson E, Gay L, et al. Comprehensive genomic profiling of 282 pediatric low- and high-grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures. Oncologist. 2017 Dec;22(12):1478–1490..
   PubMed Web of Science ®Google Scholar
• Soliman H, Mediavilla-Varela M, Antonia S. Indoleamine 2,3-dioxygenase: is it an immune suppressor? Cancer J. 2010 Jul-Aug;16(4):354–359.
   PubMed Web of Science ®Google Scholar
• Hanihara M, Kawataki T, Oh-Oka K, et al. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model. J Neurosurg. 2016 Jun;124(6):1594–1601.
   PubMed Web of Science ®Google Scholar
• Pollack IF, Jakacki RI, Butterfield LH, et al. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol. 2014 Jul 1;32(19):2050–2058.
   PubMed Web of Science ®Google Scholar
• Pollack IF, Jakacki RI, Butterfield LH, et al. Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. J Neurooncol. 2016 Dec;130(3):517–527.
   PubMed Web of Science ®Google Scholar
• Ochs K, Ott M, Bunse T, et al. K27M-mutant histone-3 as a novel target for glioma immunotherapy. Oncoimmunology. 2017;6(7):e1328340.
   PubMed Web of Science ®Google Scholar
• Liau LM, Ashkan K, Tran DD, et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018 May 29;16(1):142.
   PubMedGoogle Scholar
• Benitez-Ribas D, Cabezon R, Florez-Grau G, et al. Immune response generated with the administration of autologous dendritic cells pulsed with an allogenic tumoral cell-lines lysate in patients with newly diagnosed diffuse intrinsic pontine glioma. Front Oncol. 2018;8:127.
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013 Apr 18;368(16):1509–1518.
   PubMed Web of Science ®Google Scholar
• Wang SS, Bandopadhayay P, Jenkins MR. Towards immunotherapy for pediatric brain tumors. Trends Immunol. 2019 Aug;40(8):748–761.
   PubMed Web of Science ®Google Scholar
• Majzner RG, Theruvath JL, Nellan A, et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin Cancer Res. 2019 Apr 15;25(8):2560–2574.
   PubMed Web of Science ®Google Scholar
• Mount CW, Majzner RG, Sundaresh S, et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(+) diffuse midline gliomas. Nat Med. 2018 May;24(5):572–579.
   PubMed Web of Science ®Google Scholar